ClinicalTrials.gg
CompletedNCT00976521Updated Jul 8, 2013Results posted

The INFUSE - Anterior Myocardial Infarction (AMI) Study

An interventional study of Abciximab local infusion and No local infusion in Acute Anterior Myocardial Infarction, sponsored by Atrium Medical Corporation. Completed at 38 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-08.

Sponsored by Atrium Medical Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites. Subjects who present with anterior ST-elevation myocardial infarction (STEMI) and an occluded proximal or mid left anterior descending (LAD) with TIMI 0/1/2 flow will be eligible for randomization to one of the following arms:

  1. Local infusion of abciximab following thrombus aspiration
  2. Local infusion of abciximab and no thrombus aspiration
  3. No local infusion and thrombus aspiration
  4. No local infusion and no thrombus aspiration

In addition, a cardiac magnetic resonance imaging (MRI) sub-study evaluating microvascular obstruction (MVO) will be performed with up to 160 subjects at up to 20 sites.

Read the detailed description

The primary objective of the study is to demonstrate that among subjects undergoing primary PCI for anterior STEMI treated with a bivalirudin monotherapy anticoagulation strategy, the intracoronary infusion of an abciximab bolus with or without thrombus aspiration prior to stent implantation, compared to no infusion with or without thrombus aspiration (standard of care), results in 1) reduced infarct size measured by cardiac MRI at 30 days (range -7 days/+14 days; i.e., between 23 and 44 days), 2) reduce microvascular obstruction (MVO) by cardiac MRI at 5 + 2 days (i.e., between 3 and 7 days), 3) enhanced ST-segment resolution, 4) improved myocardial perfusion, 5) reduced thrombus burden and angiographic complications, and 6) no increase in major and minor bleeding.

02

Conditions studied

  • Acute Anterior Myocardial Infarction
03

In context

Anterior Wall Myocardial Infarction

36 studies on the registry are indexed under Anterior Wall Myocardial Infarction; 5 are open to participants now.

This study's enrollment of 452 is above the median of 110 across 28 interventional studies indexed under Anterior Wall Myocardial Infarction.

Browse Anterior Wall Myocardial Infarction studies →

Lead sponsor

Atrium Medical Corporation is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The subject must be >18 years of age;
  • Subject is experiencing clinical symptoms consistent with AMI (e.g., chest pain, arm pain, etc.,) >30 minutes duration and unresponsive to nitroglycerin;
  • Anterior MI with showing at least 1 mm of ST-segment elevation in 2 or more contiguous leads in V1-V4, or new (or presumably new) left bundle branch block;
  • Anticipated symptom onset to balloon or aspiration time of ≤5 hours;
  • The subject and his/her physician are willing to comply with specified follow-up evaluations;
  • The subject or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided and signed written , approved by the appropriate Medical Ethics Committee (MEC) or Institutional Review Board (IRB)
  • Infarct artery located in the proximal or mid left anterior descending coronary artery, with TIMI 0/1/2 flow at the time of initial diagnostic angiography (prior to wire passage);
  • Based on coronary anatomy, PCI is indicated for revascularization;
  • Only one epicardial coronary artery will be treated;
  • Expected ability to deliver a ClearWay™ RX Infusion Catheter to the infarct lesion (absence of excessive tortuosity, diffuse disease or moderate/heavy calcification).

Key Exclusion Criteria:

  • Prior myocardial infarction, or known prior systolic dysfunction (known \<40% by any prior measure or regional wall motion abnormalities);
  • An elective surgical procedure is planned that would necessitate interruption of anti- agents during the first twelve months post enrollment;
  • Subjects who previously underwent coronary stent implantation and in whom coronary angiography demonstrates stent thrombosis to be the cause of the AMI;
  • Subject has previously undergone an angioplasty or stenting procedure in the left anterior descending artery;
  • Definite planned use of aspiration, atherectomy, thrombectomy and/or distal protection catheters prior to PTCA or stent implantation (other than in subjects randomized to thrombus aspiration);
  • Any to undergo MRI imaging.
  • Multivessel intervention required during the index procedure (subjects may be enrolled if treatment of more than one lesion in the LAD or its branches is required, however) (planned staged procedures are permitted with strong recommendation to be performed after 30-day clinical and MRI endpoints are completed);
  • Severe vessel tortuosity, diffuse disease or severe calcification is present which may impede successful delivery of the ClearWay™ RX Infusion Catheter or the Export® Aspiration Catheter;
  • Features are present highly unfavorable for PCI;
  • Target lesion is present within a bypass graft conduit;
  • MI is due to thrombosis within or adjacent to a previously implanted stent;
  • Left ventriculography demonstrates severe mitral regurgitation or a VSD;
  • Unprotected left main stenosis >40% or that will require intervention
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
452 participants (actual)

Study arms

  • Experimental
    Local infusion, thrombus aspiration

    Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.

    Drug: Abciximab local infusion · Procedure: Thrombus aspiration

  • Experimental
    Local infusion, no aspiration

    Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration

    Drug: Abciximab local infusion

  • Active comparator
    No local infusion, thrombus aspiration

    No local infusion of abciximab, thrombus aspiration.

    Other: No local infusion · Procedure: Thrombus aspiration

  • Active comparator
    No local infusion, no aspiration

    No local infusion abciximab and no thrombus aspiration

    Other: No local infusion

Interventions

  • DrugAbciximab local infusion

    Local infusion of abciximab using the ClearWay™ RX Infusion Catheter

  • OtherNo local infusion

    Intervention without local infusion

  • ProcedureThrombus aspiration

    Thrombus aspiration

06

What researchers measure

Primary outcomes

  1. Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion

    The primary endpoint of the INFUSE AMI study is infarct size as a percentage of total left ventricular mass at 30 days as measured by cardiac MRI (cMRI), comparing the pooled randomized active (abciximab) infusion to the pooled non infusion arms, without regard to aspiration.

    Time frame: 30 Days Post Index Procedure

Secondary outcomes

  1. Major Secondary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Aspiration vs. No Aspiration

    The major secondary endpoint of the INFUSE AMI Study is infarct size as a percentage of total myocardial mass at 30 days measured by cardiac MRI (cMRI), comparing the pooled randomized aspiration arms to the pooled no aspiration arms, without regard to abciximab infusion.

    Time frame: 30 Days

07

Results

Posted Jul 8, 2013

Participant flow

Between 28-Nov-09 and 02-Dec-11, 452 subjects meeting all clinical eligibility criteria were consented and enrolled at 37 US and European sites.

Participant flow — Overall Study
MilestoneLocal Infusion, Thrombus AspirationLocal Infusion, no AspirationNo Local Infusion, Thrombus AspirationNo Local Infusion, no Aspiration
Started118111111112
Completed1099910293
Not completed912919

Outcome measures

PrimaryPrimary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion

The primary endpoint of the INFUSE AMI study is infarct size as a percentage of total left ventricular mass at 30 days as measured by cardiac MRI (cMRI), comparing the pooled randomized active (abciximab) infusion to the pooled non infusion arms, without regard to aspiration.

Time frame:
30 Days Post Index Procedure
Reported as:
Median · Percentage of Left Ventricular Mass
Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion
Percentage of Left Ventricular MassAbciximab InfusionNo InfusionCombined
Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion15.1 (6.8 to 22.7)17.9 (10.3 to 25.4)17.2 (7.4 to 23.6)
Statistical analysis
  • Abciximab Infusion vs No Infusion · Wilcoxon (Mann-Whitney) · p = 0.034
SecondaryMajor Secondary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Aspiration vs. No Aspiration

The major secondary endpoint of the INFUSE AMI Study is infarct size as a percentage of total myocardial mass at 30 days measured by cardiac MRI (cMRI), comparing the pooled randomized aspiration arms to the pooled no aspiration arms, without regard to abciximab infusion.

Time frame:
30 Days
Reported as:
Median · Percentage of Total Myocardial Mass
Major Secondary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Aspiration vs. No Aspiration
Percentage of Total Myocardial MassThrombus AspirationNo AspirationCombined
Major Secondary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Aspiration vs. No Aspiration17.0 (9.0 to 22.8)17.3 (7.1 to 25.5)17.2 (7.4 to 23.6)
Statistical analysis
  • Thrombus Aspiration vs No Aspiration · Wilcoxon (Mann-Whitney) · p = 0.51

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Local Infusion, Thrombus Aspiration—31/118 (26.3%)—
Local Infusion, No Aspiration—31/111 (27.9%)—
No Local Infusion, Thrombus Aspiration—35/111 (31.5%)—
No Local Infusion, No Aspiration—41/112 (36.6%)—
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventLocal Infusion, Thrombus AspirationLocal Infusion, No AspirationNo Local Infusion, Thrombus AspirationNo Local Infusion, No Aspiration
Heart failureCardiac disorders2/1184/1114/11111/112
Angina pectorisCardiac disorders7/1187/1116/1115/112
Cardiac deathGeneral disorders5/1182/1112/1112/112
Congestive heart failureCardiac disorders1/1183/1111/1110/112
Intracardiac thrombusCardiac disorders2/1183/1113/1110/112
Cardiogenic shockCardiac disorders1/1181/1110/1113/112
GI bleedGastrointestinal disorders1/1180/1111/1113/112
Myocardial infarctionCardiac disorders0/1181/1112/1111/112
Chest painGeneral disorders2/1181/1112/1112/112
Chest pain (non-cardiac)General disorders0/1180/1112/1110/112

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Local Infusion, Thrombus AspirationLocal Infusion, no AspirationNo Local Infusion, Thrombus AspirationNo Local Infusion, no AspirationTotal
<=18 years00000
Between 18 and 65 years80796167287
>=65 years38325045165
Age Continuous
Age Continuous(years)Local Infusion, Thrombus AspirationLocal Infusion, no AspirationNo Local Infusion, Thrombus AspirationNo Local Infusion, no AspirationTotal
Median60.0 (52.0 to 66.0)56.0 (49.0 to 68.0)62.0 (53.0 to 73.0)62.5 (52.5 to 71.0)61.0 (52.0 to 72.0)
Sex: Female, Male
Sex: Female, Male(Participants)Local Infusion, Thrombus AspirationLocal Infusion, no AspirationNo Local Infusion, Thrombus AspirationNo Local Infusion, no AspirationTotal
Female34272631118
Male84848581334
Region of Enrollment
Region of Enrollment(participants)Local Infusion, Thrombus AspirationLocal Infusion, no AspirationNo Local Infusion, Thrombus AspirationNo Local Infusion, no AspirationTotal
United States1415121253
Poland2524272399
Austria131411947
Netherlands1411101550
Germany2221191981
United Kingdom30263234122
08

Study locations

38 sites
  • Washington Adventist Hospital
    Takoma Park, Maryland 20912, United States
  • Carolinas Medical Center-SHVI
    Charlotte, North Carolina 28203, United States
  • Moses Cone Vascular Center
    Greensboro, North Carolina 27401, United States
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
  • Harrisburg Hospital/ Pinnacle Health
    Harrisburg, Pennsylvania 17110, United States
  • Wellmont Holston Valley Medical Center
    Kingsport, Tennessee 37660, United States
  • Sentara Virginia Beach General Hospital
    Virginia Beach, Virginia 23454, United States
  • Landeskrankenhaus Braunau/Simbach
    Braunau, 5280, Austria
  • Landeskrankenhaus Bruck/Mur
    Bruck/Mur, 8600, Austria
  • Landeskrankenhaus Graz West
    Graz, 8020, Austria
  • Univ. Klinik für Innere Medizin III Innsbruck
    Innsbruck, 6020, Austria
  • Univ. Klinik für Innere Medizin II
    Vienna, 1090, Austria
  • Charite- University Medicine Campus Benjamin Franklin
    Berlin, D-12200, Germany
  • Klinikum Villingen Kardiologie
    Darmstadt, 64283, Germany
  • Facharzt fur Innere Medizin/Kardiologie
    Ludwigshafen, D-67063, Germany
  • Universitätsmedizin Mannheim - I. Medizinische Klinik
    Mannheim, 68167, Germany
  • Klinikum der Universität Regensburg
    Regensburg, 93053, Germany
  • Universtitätsklinikuim Ulm
    Ulm, 89081, Germany
  • Ziekenhuis Rijnstate
    Arnhem, NL 6815 AD, Netherlands
  • Catharina Hospital Eindhoven
    Eindhoven, 5623 EJ, Netherlands
  • Isala Klinieken, Locatie de Weezenlanden
    Zwolle, 8011 JW, Netherlands
  • Polsko - Amerykańskie Kliniki Serca II Oddział Kardiologiczny American Heart of Poland Sp. z o.o.
    Bielsko-Biała, 43316, Poland
  • Krakowskie Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii
    Krakow, 30693, Poland
  • Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie, Centrum Interwencyjne Leczenia Chorób Serca i Naczyń
    Kraków, 31102, Poland
  • SPZOZ Szpital Uniwersytecki w Krakowie, Samodzielna Pracownia Hemodynamiki i Angiografii
    Kraków, 31501, Poland
  • Pracownia Hemodynamiki Oddziału Kardiologicznego Wojewódzkiego Centrum Medycyny w Opolu
    Opole, 45418, Poland
  • Centrum Kardiologii Inwazyjnej GVM Carint
    Oswiecim, 32600, Poland
  • Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie Pracownia Hemodynamiki I Katedry i Kliniki Kardiologii
    Warszawa, 2097, Poland
  • Instytut Kardiologii im. Prymasa Tysiąclecia Kardynała Stefana Wyszyńskiego,I Samodzielna Pracownia Hemodynamiki
    Warszawa, 4628, Poland
  • University Hospitals of Leicester - Glenfield Hospital
    Leicester, U.k. LE3 9QP, United Kingdom
  • King's College Hospital
    London, U.k. SE5 9RS, United Kingdom
  • Manchester Royal Infirmary
    Manchester, U.k. M13 9WL, United Kingdom
  • Wythenshawe Hospital
    Manchester, U.k. M23 9LT, United Kingdom
  • Southampton University Hospital
    Southampton, U.k. SO16 6UD, United Kingdom
  • Royal Victoria Hospital, Belfast Trust
    Belfast, BT12 6BA, United Kingdom
  • Bristol Heart Institute
    Bristol, BS2 8HW, United Kingdom
  • Golden Jubilee National Hospital
    Glasgow, G81 4DY, United Kingdom
  • Freeman Hospital
    Newcastle-upon-Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Giustino G, Redfors B, Brener SJ, Kirtane AJ, Genereux P, Maehara A, Dudek D, Neunteufl T, Metzger DC, Crowley A, Mehran R, Gibson CM, Stone GW. Correlates and prognostic impact of new-onset heart failure after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the INFUSE-AMI trial. Eur Heart J Acute Cardiovasc Care. 2018 Jun;7(4):339-347. doi: 10.1177/2048872617719649. Epub 2017 Aug 22. PubMed 28828881 ↗
  • Tomey MI, Mehran R, Brener SJ, Maehara A, Witzenbichler B, Dizon JM, El-Omar M, Xu K, Gibson CM, Stone GW. Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: an analysis of intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI). Am Heart J. 2015 Jan;169(1):86-93. doi: 10.1016/j.ahj.2014.06.019. Epub 2014 Jul 3. PubMed 25497252 ↗
  • Guerchicoff A, Brener SJ, Maehara A, Witzenbichler B, Fahy M, Xu K, Gersh BJ, Mehran R, Gibson CM, Stone GW. Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). JACC Cardiovasc Interv. 2014 Jul;7(7):733-40. doi: 10.1016/j.jcin.2014.01.166. PubMed 25060015 ↗
  • Stone GW, Witzenbichler B, Godlewski J, Dambrink JH, Ochala A, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Dizon JM, Wolff SD, Brener SJ, Mehran R, Maehara A, Gibson CM. Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: one-year results from the INFUSE-AMI trial. Circ Cardiovasc Interv. 2013 Oct 1;6(5):527-34. doi: 10.1161/CIRCINTERVENTIONS.113.000644. Epub 2013 Oct 1. PubMed 24084626 ↗
  • Brener SJ, Maehara A, Dizon JM, Fahy M, Witzenbichler B, Parise H, El-Omar M, Dambrink JH, Mehran R, Oldroyd K, Gibson CM, Stone GW. Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial. JACC Cardiovasc Interv. 2013 Jul;6(7):718-24. doi: 10.1016/j.jcin.2013.03.013. PubMed 23866184 ↗
  • Brener SJ, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar M, Dambrink JH, Genereux P, Mehran R, Oldroyd K, Parise H, Gibson CM, Stone GW. Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. Am Heart J. 2013 Jul;166(1):64-70. doi: 10.1016/j.ahj.2013.03.029. Epub 2013 Apr 30. PubMed 23816023 ↗
  • Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM; INFUSE-AMI Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012 May 2;307(17):1817-26. doi: 10.1001/jama.2012.421. Epub 2012 Mar 25. PubMed 22447888 ↗
  • Gibson CM, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW. Rationale and design of the INFUSE-AMI study: A 2 x 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. Am Heart J. 2011 Mar;161(3):478-486.e7. doi: 10.1016/j.ahj.2010.10.006. Epub 2011 Jan 28. PubMed 21392601 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Feb 2012 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2009
First posted
Sep 14, 2009
Start
Sep 2009
Primary completionActual
Feb 2012
CompletionActual
Apr 2013
Results first posted
Jul 8, 2013
Last update
Jul 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00976521
Lead sponsor
Atrium Medical Corporation
Responsible party
Sponsor
First posted
Sep 14, 2009
Start date
Sep 2009
Primary completion
Feb 2012
Completion
Apr 2013
Results posted
Jul 8, 2013
Last update
Jul 8, 2013

Study contacts

Greg W Stone, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion